Published in Proc Natl Acad Sci U S A on December 07, 1999
Human telomerase and its regulation. Microbiol Mol Biol Rev (2002) 3.11
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
RNA binding domain of telomerase reverse transcriptase. Mol Cell Biol (2001) 2.27
Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol (2002) 2.25
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Natural and pharmacological regulation of telomerase. Nucleic Acids Res (2002) 1.92
Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A (2001) 1.87
Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc Natl Acad Sci U S A (2001) 1.83
A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J (2001) 1.79
Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci U S A (2002) 1.75
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res (2001) 1.73
Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol Cell Biol (2001) 1.72
Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci U S A (2001) 1.69
The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia (2001) 1.60
An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia (2001) 1.48
Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife (2015) 1.28
Processive and distributive extension of human telomeres by telomerase under homeostatic and nonequilibrium conditions. Mol Cell (2011) 1.26
Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase. Mol Cell Biol (2000) 1.22
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol (2008) 1.22
From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res (2010) 1.22
The human Pif1 helicase, a potential Escherichia coli RecD homologue, inhibits telomerase activity. Nucleic Acids Res (2006) 1.19
The length of telomeric G-rich strand 3'-overhang measured by oligonucleotide ligation assay. Nucleic Acids Res (2001) 1.14
A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A (2006) 1.13
Telomeres, telomerase, and tumorigenesis--a review. MedGenMed (2004) 1.11
Telomerase and its potential for therapeutic intervention. Br J Pharmacol (2007) 1.11
Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol (2004) 1.10
The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango. Virology (2008) 1.07
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol (2014) 1.06
Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro. Nucleic Acids Res (2002) 1.05
Recombination-based telomere maintenance is dependent on Tel1-MRN and Rap1 and inhibited by telomerase, Taz1, and Ku in fission yeast. Mol Cell Biol (2007) 1.04
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res (2004) 1.04
Analysis of telomerase in Candida albicans: potential role in telomere end protection. Eukaryot Cell (2002) 1.03
POT1 association with TRF2 regulates telomere length. Mol Cell Biol (2009) 1.01
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res (2005) 0.98
Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One (2010) 0.98
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer (2005) 0.97
Alterations of DNA and chromatin structures at telomeres and genetic instability in mouse cells defective in DNA polymerase alpha. Mol Cell Biol (2005) 0.97
The role of telomerase expression and telomere length maintenance in human and mouse. J Clin Immunol (2000) 0.97
Inhibition of human telomerase in MKN-45 cell line by antisense hTR expression vector induces cell apoptosis and growth arrest. World J Gastroenterol (2002) 0.94
The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo. RNA (2001) 0.94
The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancers (Basel) (2010) 0.93
Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci U S A (2001) 0.93
Altered states of telomere deprotection and the two-stage mechanism of replicative aging. Mol Cell Biol (2009) 0.91
Molecular regulation of telomerase activity in aging. Protein Cell (2011) 0.90
Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity. Biochem Biophys Res Commun (2012) 0.89
Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress. PLoS One (2010) 0.89
Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine. Bioorg Med Chem Lett (2009) 0.86
Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther (2010) 0.86
Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res (2001) 0.86
γ Sulphate PNA (PNA S): highly selective DNA binding molecule showing promising antigene activity. PLoS One (2012) 0.86
Allosteric inhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates. Nucleic Acids Res (2002) 0.85
Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells. Mol Cell Biol (2006) 0.85
Inhibition of telomerase by linear-chain fatty acids: a structural analysis. Biochem J (2002) 0.84
PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. J Cell Mol Med (2009) 0.84
Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie (2007) 0.83
Destabilization of tRNA3(Lys) from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog. Nucleic Acids Res (2001) 0.83
Effect of antisense oligodeoxynucleotide of telomerase RNA on telomerase activity and cell apoptosis in human colon cancer. World J Gastroenterol (2004) 0.83
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
Biophysical characterization of an ensemble of intramolecular i-motifs formed by the human c-MYC NHE III1 P1 promoter mutant sequence. Biophys J (2010) 0.82
Design of a ribozyme targeting human telomerase reverse transcriptase and cloning of it's gene. World J Gastroenterol (2003) 0.82
Telomerase as a tumor-associated antigen for cancer immunotherapy. Cytotechnology (2004) 0.81
Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. EMBO Mol Med (2015) 0.81
Telomerase confers resistance to caspase-mediated apoptosis. Clin Interv Aging (2006) 0.81
Methods for assessing DNA hybridization of peptide nucleic acid-titanium dioxide nanoconjugates. Anal Biochem (2008) 0.81
Telomerase activation and rejuvenation of telomere length in stimulated T cells derived from serially transplanted hematopoietic stem cells. J Exp Med (2002) 0.81
Telomeres and telomerase: from discovery to clinical trials. Chem Biol (2009) 0.80
Mapping targetable sites on human telomerase RNA pseudoknot/template domain using 2'-OMe RNA-interacting polynucleotide (RIPtide) microarrays. J Biol Chem (2012) 0.80
Targeting human telomerase for cancer therapeutics. Cytotechnology (2004) 0.79
The tamoxifen-induced suppression of telomerase activity in the human hepatoblastoma cell line HepG2: a result of post-translational regulation. J Cancer Res Clin Oncol (2004) 0.78
Biochemical properties of Trypanosoma cruzi telomerase. Nucleic Acids Res (2004) 0.78
Enhanced telomere shortening in transformed lymphoblasts from patients with X linked dyskeratosis. J Clin Pathol (2003) 0.78
Increased Stability of Nucleolar PinX1 in the Presence of TERT. Mol Cells (2015) 0.78
Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J Mol Diagn (2004) 0.77
Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis. Clin Exp Gastroenterol (2011) 0.77
RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth. Oncotarget (2015) 0.77
Complex regulation of telomerase activity: implications for cancer therapy. Am J Pathol (2001) 0.76
Therapeutic Targeting of Telomerase. Genes (Basel) (2016) 0.76
Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res (2008) 0.76
Role of Telomerase in the Cardiovascular System. Genes (Basel) (2016) 0.76
Expression of telomerase & its significance in the diagnosis of pancreatic cancer. Indian J Med Res (2012) 0.76
Effective inhibition of cancer cell growth by a novel tripartite transfection complex containing ribbon antisense molecules to hTR. Cancer Res Treat (2004) 0.75
An integrated overview of spatiotemporal organization and regulation in mitosis in terms of the proteins in the functional supercomplexes. Front Microbiol (2014) 0.75
Treating Cancer by Targeting Telomeres and Telomerase. Antioxidants (Basel) (2017) 0.75
A small molecule inhibitor of Pot1 binding to telomeric DNA. Biochemistry (2012) 0.75
Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochim Biophys Acta (2016) 0.75
Keeping those telomeres short! an innovative intratumoral long-term drug delivery system. J Cancer Res Clin Oncol (2014) 0.75
Single Stem Cell Imaging and Analysis Reveals Telomere Length Differences in Diseased Human and Mouse Skeletal Muscles. Stem Cell Reports (2017) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell (1997) 13.34
Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science (1991) 12.17
The RNA component of human telomerase. Science (1995) 9.86
TLC1: template RNA component of Saccharomyces cerevisiae telomerase. Science (1994) 9.08
The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell (1989) 8.68
Essential role of mouse telomerase in highly proliferative organs. Nature (1998) 7.23
Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell (1999) 6.98
An alternative pathway for yeast telomere maintenance rescues est1- senescence. Cell (1993) 6.89
In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature (1990) 6.82
Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med (1997) 6.55
p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell (1999) 5.93
Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol (1998) 4.59
Runaway telomere elongation caused by telomerase RNA gene mutations. Nature (1995) 4.34
Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A (1998) 4.11
Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A (1994) 3.86
Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med (1995) 3.74
Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem (1997) 2.66
Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell (1999) 2.46
Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol (1999) 1.94
Telomerase and cancer: revisiting the telomere hypothesis. Trends Biochem Sci (1996) 1.93
Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol (1996) 1.79
Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res (1997) 1.68
Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol (1995) 1.62
Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst (1996) 1.57
Telomere shortening in mTR-/- embryos is associated with failure to close the neural tube. EMBO J (1999) 1.49
Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol (1997) 1.38
Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A (1997) 1.35
Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J Biol Chem (1998) 1.33
Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene (1999) 1.31
First "antisense" drug will treat CMV retinitis. JAMA (1998) 1.28
Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res (1995) 1.24
Keeping the biotechnology of antisense in context. Nat Biotechnol (1999) 1.22
Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol (1999) 1.16
High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst (1997) 1.15
Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol (1997) 1.13
Inhibition of human telomerase by 2'-O-methyl-RNA. Proc Natl Acad Sci U S A (1998) 1.09
For better or worse? Telomerase inhibition and cancer. Cell (1999) 1.06
Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer (1998) 1.04
Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates. Anal Biochem (1999) 0.98
Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med Chem Lett (1998) 0.93
An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev (1999) 0.89
Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res (1997) 0.86
Controversies in the cellular pharmacology of oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1997) 0.83
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet (1997) 6.69
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell (1991) 6.48
Telomerase activity in human germline and embryonic tissues and cells. Dev Genet (1996) 5.00
Positive autoregulation of the myogenic determination gene MyoD1. Cell (1989) 4.28
Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet (1999) 4.22
A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res (1991) 4.07
Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature (2000) 3.96
Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol (1989) 3.89
Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med (1995) 3.74
Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta (1991) 3.73
Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature (1989) 3.73
Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev (1997) 3.42
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol (2001) 3.26
Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol (1995) 3.20
Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev (1999) 3.19
Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res (1995) 3.16
Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev (2001) 3.16
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Evidence for in vivo but not in vitro expression of a Borrelia burgdorferi outer surface protein F (OspF) homologue. Mol Microbiol (1995) 2.92
Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med (2000) 2.81
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
Telomere position effect in human cells. Science (2001) 2.61
Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res (1994) 2.28
Telomerase and cancer. Hum Mol Genet (2001) 2.28
Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet (1998) 2.27
E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene (1993) 2.25
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene (1994) 2.18
Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol (2000) 2.15
Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem (2000) 2.14
Telomerase activity in human cancer. Curr Opin Oncol (1996) 2.13
Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res (1995) 2.11
Telomerase activity in gastric cancer. Cancer Res (1995) 2.02
Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins. Mol Cell Biol (1994) 2.00
The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol (1993) 1.98
Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res (1989) 1.96
Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro. Mol Cell Biol (1999) 1.96
The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet (2000) 1.93
Telomere positional effects and the regulation of cellular senescence. Trends Genet (1992) 1.90
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res (1994) 1.88
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res (1996) 1.87
Regulation of telomerase activity in immortal cell lines. Mol Cell Biol (1996) 1.82
Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge. Nat Biotechnol (1996) 1.78
Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev (2001) 1.78
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res (2001) 1.73
Telomerase activity in human breast tumors. J Natl Cancer Inst (1996) 1.73
Telomere shortening is proportional to the size of the G-rich telomeric 3'-overhang. J Biol Chem (2000) 1.73
Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes. Cell Tissue Res (1992) 1.67
Characterization of outer membranes isolated from Borrelia burgdorferi, the Lyme disease spirochete. Infect Immun (1995) 1.66
Telomerase activity in human brain tumours. Lancet (1995) 1.64
Biliary excretion of cephalosporins in rats: influence of molecular weight. Antimicrob Agents Chemother (1980) 1.63
Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res (1995) 1.60
Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene (1993) 1.59
Normal human telomeres are not late replicating. Exp Cell Res (1999) 1.57
Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol (1999) 1.55
Urea extraction of Z bands, intercalated disks, and desmosomes. J Ultrastruct Res (1968) 1.54
Transient expression of human telomerase extends the life span of normal human fibroblasts. Biochem Biophys Res Commun (2000) 1.54
Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci U S A (1985) 1.54
Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet (1997) 1.52
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
Formation of anucleate and multinucleate cells in normal and SV 40 transformed WI-38 by cytochalasin B. Exp Cell Res (1972) 1.50
A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics (1998) 1.48
An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia (2001) 1.48
Telomerase immortalization of human myometrial cells. Biol Reprod (2002) 1.48
Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. Immunity (2000) 1.47
Role of telomerase in cellular proliferation and cancer. J Cell Physiol (1999) 1.47
Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol (1996) 1.46
Increasing trends in the use of breast-conserving surgery in California. Am J Public Health (2000) 1.44
Leukaemia in workers exposed to electrical and magnetic fields. Lancet (1982) 1.43
Telomeres and telomerase: a simple picture becomes complex. Cell (1996) 1.41
Cyclic amplification and selection of targets for multicomponent complexes: myogenin interacts with factors recognizing binding sites for basic helix-loop-helix, nuclear factor 1, myocyte-specific enhancer-binding factor 2, and COMP1 factor. Proc Natl Acad Sci U S A (1992) 1.41
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Multiple myeloma in cosmetologists. Am J Ind Med (1982) 1.38
Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol (1995) 1.36
Induction of muscle genes in neural cells. J Cell Biol (1984) 1.36
High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res (2000) 1.36
Cilia in cardiac differentiation. J Ultrastruct Res (1969) 1.35